Clarient, Inc. (CLRT) news stock charts
Clarient, Inc. (CLRT) Investment Summary:
Clarient, Inc., a Delaware corporation ("Clarient", the "Company", "we", "us" or "our"), was founded and organized in 1993 and is headquartered in Aliso Viejo, California. Our vision is to improve the lives of those affected by cancer by bringing clarity to a complex disease. Our mission is to be the leader in cancer diagnostics by dedicating ourselves to collaborative relationships with the health care community as we translate cancer discovery and information into better patient care. With the completion of the human genome project in the late 1990s, medical science has entered a new era of diagnostics that will move us closer than ever before to understanding the molecular causes for complex diseases, particularly cancer. As a result, the landscape of cancer management is undergoing significant change. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f04%2f01%2f0001047469-08-003889.html#FIS_BUSINESS"www.clarientinc.com
Founded in 1993
CLARIENT INC (CLRT:NASDAQ)
LAST $2.61 USD
CHANGE TODAY -0.025 -0.95%
VOLUME 167.8K
As of 12:38 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of CLARIENT INC (CLRT)
|
OPEN
$2.65
|
PREVIOUS CLOSE
$2.63
|
|
|
DAY HIGH
$2.66
|
DAY LOW
$2.60
|
|
|
52 WEEK HIGH
09/22/09 - $4.43
|
52 WEEK LOW
03/23/09 - $1.64
|
|
|
MARKET CAP
204.3M
|
AVERAGE VOLUME 10 D
476.0K
|
|
|
EPS TTM
$-0.16
|
SHARES OUTSTANDING
78.4M
|
|
|
CLRT Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Stocks on the Move: Boeing, ConAgra, Jabil Circuit
12/22/2009 11:10 AM ET
Plus more stocks making headlines in Tuesday's market
Key developments for CLARIENT INC (CLRT)
Clarient, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2009; Provides Earnings Guidance for the Year 2010
03/10/2010
Clarient, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2009. Fourth quarter 2009 net revenue was $23.3 million, compared to $21.9 million for the same period in 2008. Operating loss for the fourth quarter of 2009 was $2.3 million compared with operating income of $184,000 for the same period of 2008. Net loss applicable to common stockholders for the quarter was $2.7 million, or $0.03 per basic and diluted share compared to $2.2 million, or $0.03 per basic and diluted share reported last year. Loss from continuing operations, net of income taxes was $2.7 million or $0.03 per basic and diluted share compared to $2.2 million or $0.03 per basic and diluted share reported last year. Adjusted EBITDA loss for the quarter was $0.5 million against adjusted EBITDA of $1 million reported last year. Operating results for the current quarter and the year were impacted by severance of $0.7 million as well as one-time transaction-related expenses of $0.8 million including $0.5 million from corporate development opportunities in early 2009 that did not transpire. Net revenue for the full year was $91.6 million, a 24% increase over the $73.7 million earned in 2008. For the full year 2009, operating loss was $3.1 million versus an operating loss of $1.5 million for the twelve months ended December 31, 2008. For the full year 2009, the net loss was $6.1 million, or $0.08 per share. However, the net loss applicable to common stockholders for the year was $10.3 million, or $0.13 per basic and diluted share compared to $9.6 million, or $0.13 per basic and diluted share reported last year. Net loss applicable to common stockholders for the year included a non-recurring $4.3 million non-cash deemed dividend arising from a "beneficial conversion feature" relating to the May 2009 tranche of the preferred stock private placement transaction with Oak Investment Partners. Loss from continuing operations, net of income taxes was $7.6 million or $0.14 per basic and diluted share compared to $9.6 million or $0.13 per basic and diluted share reported last year. Adjusted EBITDA for the year was $3.1 million against $3.5 million reported last year. Based on Clarient's current revenue run rate, anticipated new product introductions and other market factors, Clarient expects net revenue for the full year 2010 to range between $108 million to $115 million. This increase would represent a year-over-year growth rate of between 18% and 25% from 2009 net revenue. The company also indicated that it is expecting to report net income for the 2010 fiscal year.
Clarient, Inc. expected to Report Q1 2010 Results on May 6, 2010. This event was calculated by Capital IQ (Created on March 10, 2010).
03/10/2010
Clarient, Inc. expected to Report Q1 2010 Results on May 6, 2010. This event was calculated by Capital IQ (Created on March 10, 2010).
Clarient, Inc. to Report Q4, 2009 Results on 03/10/2010
02/24/2010
Clarient, Inc. announced that they will report Q4, 2009 results on 03/10/2010
Clarient, Inc. financial resources
CLRT Competitors
| Company | Last | Change |
| AVEO Pharmaceuticals Inc | $8.77 USD | -0.07 |
| CytoCore Inc | $0.13 USD | -0.052 |
| Exiqon A/S | kr9.25 DKK | +0.25 |
| Genomic Health Inc | $18.86 USD | -0.03 |
| Genoptix Inc | $35.61 USD | -0.42 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | CLRT | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 2.3x |
|
| Price/Book | 19.7x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.9x |
Not meaningful
|
|
CLRT |
||
|
CLRT transactions
| Type Date |
Target |
|
Merger/Acquisition
December 21, 2009 |
Applied Genomics, Inc. |
More Recent Financial News About Clarient, Inc.
New Data Indicate Effectiveness of Clarient's Ovotax(TM) Test for Ovarian Cancer
2010-03-18 05:43:30
Quote:  Clarient currently expects to commercially launch the taxane product line in the fourth quarter of 2010.About Clarientwww.clarientinc.comForward Looking StatementsCertain statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and Clarient's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: Cla...Read article
Clarient Reports 2009 Fourth Quarter; Year-End Results
2010-03-17 05:49:23
Quote: ALISO VIEJO, Calif., March 10Clarient, Inc.NasdaqCLRTNews), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the fourth quarter and year ended December 31, 2009.  Fourth quarter 2009 net revenue was $23.3 million, compared to $21.9 million for the same period in 2008. Net revenue for the full year was $91.6 million, a 24 percent increase over the $73.7 million earned in 2...Read article
Clarient CEO Ron Andrews to Present at the Roth Annual OC Growth Stock Conference in Dana Point, CA
2010-03-17 05:49:23
Quote: Press ReleaseSource: Clarient, Inc.On Monday March 8, 2010, 6:00 am EST/PRNewswire-FirstCall/ -- Clarient, Inc. (: - A live webcast of the presentation will be available via a link provided at . An archived replay of the presentation will also be available for a period of 90 days from the date of the presentation at Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diag...Read article
Clarient Reports 2009 Fourth Quarter; Year-End Results
2010-03-11 07:48:37
Quote: ALISO VIEJO, Calif., March 10Clarient, Inc.NasdaqCLRTNews), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the fourth quarter and year ended December 31, 2009.  Fourth quarter 2009 net revenue was $23.3 million, compared to $21.9 million for the same period in 2008. Net revenue for the full year was $91.6 million, a 24 percent increase over the $73.7 million earned in 2...Read article
Q4 2009 Clarient, Inc. Earnings Release - After Market Close
2010-03-11 07:48:37
Quote: LTD.000607.SZTime Not SuppliedCitizens, Inc.CIATime Not SuppliedClarient, Inc.CLRTAfter Market CloseClayton Williams Energy, Inc.CWEIBefore Market OpenCLEAN ENERGY FUELS CORPCLNETime Not SuppliedCLIMATE EXCHANGE PLCCXCHF.PKTime Not SuppliedClinical Computing PlcCLC.LTime Not SuppliedCOFCO PROPERTY (GROUP) CO LTD000031.SZTime Not SuppliedCombiMatrix CorporationCBMXAfter Market CloseComverse TechnologyCMVT.PKTime Not SuppliedCOSTAIN GROUPCOST.LTime Not SuppliedDara BiosciencesDARATime Not Supplied...Read article
CLARIENT, INC Files SEC form 8-K, Results of Operations and Financial Condition
2010-03-11 07:48:36
Quote: Item 2.02 Results of Operations and Financial Condition.
On March 10, 2010, Clarient, Inc. (the "Company") issued a press release
regarding the Company's results of operations for the quarter and year ended
December 31, 2009. A copy of the press release is furnished as Exhibit 99.1 to
this Current Report on Form 8-K. This information shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
("Exchange Act") or incorp...Read article
Clarient CEO Ron Andrews to Present at the Roth Annual OC Growth Stock Conference in Dana Point, CA
2010-03-09 01:37:04
Quote: Press ReleaseSource: Clarient, Inc.On Monday March 8, 2010, 6:00 am EST/PRNewswire-FirstCall/ -- Clarient, Inc. (: - A live webcast of the presentation will be available via a link provided at . An archived replay of the presentation will also be available for a period of 90 days from the date of the presentation at Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diag...Read article
Clarient to Release 2009 Fourth Quarter and Year-End Financial Results on Wednesday, March 10th
2010-03-05 07:14:27
Quote: Press ReleaseSource: Clarient, Inc.On Wednesday February 24, 2010, 6:00 am ESTFeb./PRNewswire-FirstCall/ -- Clarient, Inc. (: - For those unable to participate in the live broadcast, a replay of the webcast will be archived at Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the healthcare community to translate cancer research and dev...Read article
Skymark Research Initiates Independent Research Coverage on Clarient, Inc.
2010-03-05 07:14:26
Quote: Press ReleaseSource: Skymark ResearchOn Wednesday March 3, 2010, 9:15 am ESTCALGARY, Alberta, March 3, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Clarient, Inc. (: - ). Skymark Research is currently offering a complimentary trial subscription. To view our research go to:Skymark Research is a leading provider of independent investment research in North America. Our services include research ana...Read article
Skymark Research Initiates Independent Research Coverage on Clarient, Inc.
2010-03-04 03:48:19
Quote: Press ReleaseSource: Skymark ResearchOn Wednesday March 3, 2010, 9:15 am ESTCALGARY, Alberta, March 3, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Clarient, Inc. (Nasdaq: - ). Skymark Research is currently offering a complimentary trial subscription. To view our research go to:Skymark Research is a leading provider of independent investment research in North America. Our services include resear...Read article
Clarient to Release 2009 Fourth Quarter and Year-End Financial Results on Wednesday, March 10th
2010-02-25 03:13:56
Quote: Press ReleaseSource: Clarient, Inc.On Wednesday February 24, 2010, 6:00 am EST/PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: - For those unable to participate in the live broadcast, a replay of the webcast will be archived at Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the healthcare community to translate cancer research and d...Read article
Clarient Launches New Lung Cancer Test
2010-02-15 03:44:11
Quote: 10 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective. The new test has been clinically validated to use in the sub-classification of patients with non-small cell lung ...Read article
Clarient CEO Ron Andrews to Present at the UBS 20th Annual Global Healthcare Services Conference in New York City
2010-02-15 03:44:11
Quote: Press ReleaseSource: Clarient, Inc.On Thursday February 4, 2010, 6:00 am ESTA live webcast of the presentation will be available via a link provided at . An archived replay of the presentation will also be available for a period of 90 days from the date of the presentation at Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the healthc...Read article
Clarient Launches New Lung Cancer Test
2010-02-10 07:39:49
Quote: 10 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective. The new test has been clinically validated to use in the sub-classification of patients with non-small cell lung ...Read article
Clarient CEO Ron Andrews to Present at the UBS 20th Annual Global Healthcare Services Conference in New York City
2010-02-05 08:48:52
Quote: Press ReleaseSource: Clarient, Inc.On Thursday February 4, 2010, 6:00 am ESTA live webcast of the presentation will be available via a link provided at . An archived replay of the presentation will also be available for a period of 90 days from the date of the presentation at Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the healthc...Read article
Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer
2010-01-26 04:01:49
Quote: 14 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, and BioView Ltd. (TASE: BIOV) today jointly announced that they will collaborate on studies to validate the clinical utility of a non-invasive test for the early detection of non-small cell lung cancer. The test, which uses a patient's sputum and was originally developed at the University of Texas M.D. Anderson Cancer Center, is exp...Read article
Clarient CEO Ron Andrews to Present at Jefferies 2010 Global Healthcare Services Conference in New York City
2010-01-26 04:01:47
Quote: Press ReleaseSource: Clarient, Inc.On Wednesday January 20, 2010, 6:00 am ESTA live webcast of the presentation will be available via a link provided at . An archived replay of the presentation will also be available for a period of 90 days from the date of the presentation at Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the health...Read article
Clarient CEO Ron Andrews to Present at Jefferies 2010 Global Healthcare Services Conference in New York City
2010-01-21 03:13:48
Quote: Press ReleaseSource: Clarient, Inc.On Wednesday January 20, 2010, 6:00 am ESTA live webcast of the presentation will be available via a link provided at . An archived replay of the presentation will also be available for a period of 90 days from the date of the presentation at Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the health...Read article
Clarient Acquires Applied Genomics, Inc.
2010-01-14 02:17:33
Quote: 21 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has acquired privately held, Huntsville, AL-based Applied Genomics, Inc. (AGI) in an all-stock merger valued at up to $17.6 million, if all conditions and milestones set forth in the merger agreement are successfully met.  As a result of the merger, AGI has become a wholly-owned subsidiary of Clarient. ÂÂ...Read article
Clarient CEO Ron Andrews to Present at J.P. Morgan 28th Annual Healthcare Conference in San Francisco
2010-01-14 02:17:31
Quote: Press ReleaseSource: Clarient, Inc.On Wednesday January 6, 2010, 6:00 am ESTA live webcast of each presentation will be available via a link provided at . Archived replays of each presentation will also be available for a period of 90 days from the date of each presentation at Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the health...Read article
Would you like to leave a comment about Clarient, Inc. CLRT
Find out what social network information about Clarient, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Clarient, Inc.'s Stock there is more great penny stock and market information at Realpennies